Arzoxifene

Generic Name: Arzoxifene

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₂₉NO_₄S

CAS Number: 182133-25-1

Unique Ingredient Identifier: E569WG6E60

Indication: Investigated for use/treatment in breast cancer, osteoporosis, and endometrial cancer.

Clinical Trials

A Study of Arzoxifene to Treat Korean Women With Osteoporosis

Phase 2

Completed

Conditions: Osteoporosis

Interventions: Drug: arzoxifene
Drug: Placebo

First Posted Date: 2008-10-07

Last Posted Date: 2015-04-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 91

Registration Number: NCT00767299

Locations: 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of

Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis

Phase 3

Completed

Conditions: Osteoporosis, Postmenopausal

Interventions: Drug: Arzoxifene
Drug: Raloxifene

First Posted Date: 2006-10-03

Last Posted Date: 2010-01-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 320

Registration Number: NCT00383422

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan

Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Hereditary Breast/Ovarian Cancer (brca1, brca2)

Interventions: Drug: arzoxifene hydrochloride
Drug: tamoxifen citrate
Other: placebo

First Posted Date: 2005-11-15

Last Posted Date: 2011-04-13

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 3

Registration Number: NCT00253539

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

Phase 4

Completed

Conditions: Breast Cancer
Endometrial Cancer
Ovarian Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2007-05-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 70

Registration Number: NCT00190697

Locations: 🇺🇸
For information regarding investigative sites for this clinical trial, call 1-877- CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or contact your personal physician, Houston, Texas, United States

Hormone Therapy in Treating Women With Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-09-13

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 114

Registration Number: NCT00003428

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer

Phase 3

Completed

Conditions: Osteoporosis, Postmenopausal

Interventions: Drug: Placebo
Drug: Arzoxifene

First Posted Date: 2004-07-20

Last Posted Date: 2010-06-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 9369

Registration Number: NCT00088010

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elk Grove, Illinois, United States

Effects of Arzoxifene on Bone Mass and the Uterus

Phase 3

Completed

Conditions: Postmenopausal Bone Loss

First Posted Date: 2004-06-22

Last Posted Date: 2007-03-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 300

Registration Number: NCT00085956

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

First Posted Date: 2004-05-25

Last Posted Date: 2012-06-07

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT00003669

Locations: 🇺🇸
Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
🇺🇸
Grant/Riverside Methodist Hospitals, Columbus, Ohio, United States
🇺🇸
U.S. Oncology, Houston, Texas, United States

and more 7 locations

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-05-21

Last Posted Date: 2012-06-07

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT00003670

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
🇺🇸
Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States

and more 1 locations

Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2003-08-29

Last Posted Date: 2017-01-13

Lead Sponsor: University of Kansas Medical Center

Registration Number: NCT00005886

Locations: 🇺🇸
Comprehensive Cancer Centers of the Desert, Palm Springs, California, United States
🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy